Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate… - Nature medicine, 2020 - nature.com
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome,. AML originates from a dominant mutation, then acquires …
AML confers an adverse outcome,. AML originates from a dominant mutation, then acquires …
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert… - Nature …, 2020 - utsouthwestern.elsevierpure.com
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims… - Nature …, 2020 - ohiostate.elsevierpure.com
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert… - Nature …, 2020 - mayoclinic.elsevierpure.com
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
[HTML][HTML] Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate… - paper.sciencenet.cn
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome1, 2. AML originates from a dominant mutation, then …
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate… - Nature Medicine, 2020 - go.gale.com
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome. sup. 1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome. sup. 1, 2. AML originates from a dominant mutation, then …
[HTML][HTML] Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims… - Nature …, 2020 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
[引用][C] Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate… - Nature Medicine, 2020 - cir.nii.ac.jp
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling:
feasibility and preliminary efficacy of the Beat AML Master Trial | CiNii Research CiNii 国立 …
feasibility and preliminary efficacy of the Beat AML Master Trial | CiNii Research CiNii 国立 …
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims… - Nature …, 2020 - pubmed.ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims… - Nature …, 2020 - ohsu.elsevierpure.com
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …
AML confers an adverse outcome 1, 2. AML originates from a dominant mutation, then …